Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide  that was being developed for inflammatory bowel diseases (IBD). ... Read more

Stock Quote

PTGX (Common Stock)
$8.87 - 0.18 (1.99%)
Exchange :NASDAQ
Volume :98,762
Today's Open$9.04
Previous Close$9.05
Data as of August 17, 2018 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $8.87 with a 52 week high of $23.97 and a 52 week low of $5.50.

Recent Press Releases

August 17, 2018

Protagonist Therapeutics Reports Granting of Inducement Award read more

August 07, 2018

Protagonist Therapeutics Reports Second Quarter 2018 Financial Results read more

August 06, 2018

Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis read more

Upcoming Events

There are currently no events scheduled.


Download Documentation Investor Presentation
Data provided by Nasdaq. Minimum 15 minutes delayed.